Brief: AUM Biosciences Receives Human Research Ethics Committee Approval To Commence Phase 2 Clinical Trial Of AUM001 For Treatment Of Metastatic Colorectal Cancer In Australia
15/11/2022 13:43
Nov 15 (Reuters) - Mountain Crest Acquisition Corp V
MCAGU.O :
* AUM BIOSCIENCES RECEIVES HUMAN RESEARCH ETHICS COMMITTEE
APPROVAL TO COMMENCE PHASE II CLINICAL TRIAL OF AUM001 FOR
TREATMENT OF METASTATIC COLORECTAL CANCER IN AUSTRALIA
Source text for Eikon: ID:nGNX1S7j9W
Further company coverage: MCAGU.O
Recent news on Mountain Crest Acquisition V
See all newsBrief: Mountain Crest Acquisition Corp. V Receives Notification Of Deficiency From Nasdaq Related To Delayed Filing Of Quarterly Reports
Brief: SPAC Mountain Crest Acquisition Corp V Receives Deficiency Notification From Nasdaq On Delayed Filing Of Annual Report, Quarterly Report
Brief: Cubebio Enter Terms Of Potential Business Combination With Mountain Crest Acquisition Corp
Brief: Mountain Crest Acquisition Corp V Got Letter From Nasdaq
Brief: Mountain Crest Acquisition Corp V Says On June 27, Co Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq